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ABSTRACT OF DISSERTATION 
NEUROPSYCHOLOGICAL CORRELATES OF STRIATAL DOPAMINERGIC 
DYSFUNCTION IN PARKINSON’S DISEASE 
Parkinson’s disease (PD) is a common neurodegenerative disorder associated with 
dysfunction of the basal ganglia, which contributes to a range of motor, cognitive, and 
affective symptoms.  Striatal dopaminergic deficits are one of the core pathological 
mechanisms thought to contribute to the extra-motor (i.e., cognitive and affective) 
symptoms in early PD.  The present study investigated the relationship between striatal 
dopaminergic integrity and cognition in 21 patients with PD and 21 age and education 
matched controls.   Each individual underwent dopamine transporter (DaT) imaging with 
single photon emission computed tomography (SPECT) (i.e., DaTscan) and standardized 
neuropsychological testing.  Strong positive associations were found between DaT 
availability in the striatum and verbal memory (r = .52-.61) and problem solving/set-
shifting (r = .55) in patients with PD.  Additional moderate to strong positive associations 
(r = .49-.56) between DaT concentrations and visuospatial functions in patients with PD 
were found.  However, similar significant associations between DaT and cognition were 
observed in age and education matched controls.  Clinically, it is important for health 
care professionals to consider the role of both striatal and extra-striatal mechanisms as 
they relate to cognition in PD.  Future studies examining the full range of pathological 
mechanisms that contribute to cognitive dysfunction in PD over time are warranted in 
order to inform more effective and targeted interventions. 
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 INTRODUCTION 
1.1 Parkinson’s Disease 
Parkinson’s disease (PD) is common neurodegenerative disorder that affects the 
central nervous system.  Approximately one million people are affected in the United 
States alone, with about 66,000 new diagnoses made each year (Kowal, Dall, Charkabati, 
Storm, & Jain, 2013).  PD is characterized clinically by parkinsonism (e.g., tremor, 
rigidity, akinesia, and postural instability) (Cummings et al., 2011; McPherson & 
Cummings, 2009).  One of the main neuropathological hallmarks of PD is dopaminergic 
neuronal loss in the substantia nigra pars compacta (SNc) and accumulation of alpha-
synuclein protein aggregates (Lewy bodies) within neurons (Gunzler, Schoenberg, Riley, 
Walter, & Maciuna, 2011; Jankovic, 2008).  Alpha-synuclein targets the autonomic 
nervous system and the brainstem in PD, resulting in loss of dopaminergic neurons in the 
SNc and other brainstem nuclei.  Protein deposition then spreads to limbic structures 
(e.g., the amygdala), the medial temporal lobe, and eventually the neocortex as the 
disease progresses (Braak, Ghebremedhin, Rüb, Bratzke, & Tredici, 2004).  Levodopa, 
the precursor for dopamine (DA), has been successful in alleviating the motor symptoms 
of PD, however, levodopa’s efficacy may decrease over time, with some patients 
requiring alternative forms of treatment such as DA agonists or deep brain stimulation 
(Gunzler, Schoenberg, Riley, Walter, & Maciuna, 2011). 
1.2 Cognitive Impairment in PD 
Much attention is often given to the motor symptoms of PD, however the wide 
range of non-motor symptoms that accompany the disease can be just as debilitating and 
are associated with reduced quality of life (Chaudhuri & Schapira, 2009).  Cognitive 
2 
impairment occurs in 20-60% of patients with PD  (Getz & Levin, 2017; Gunzler, 
Schoenberg, Riley, Walter, & Maciuna, 2011).  The most frequently associated cognitive 
impairment in PD is executive dysfunction, including problems with organization, set-
shifting, and inhibition (Kudlicka, Clare, & Hindle, 2011; Rodriquez-Oraz et al., 2009).  
Executive dysfunction is one of the earliest cognitive impairments seen in PD and is 
thought to be caused by reduced dopaminergic projections from the striatum to the frontal 
cortex (Getz & Levin, 2017; Jankovic, 2008; Kudlicka, Clare, & Hindle, 2011).  Other 
cognitive impairments seen in PD include problems with attention, working memory, 
speed of processing, language, and visuospatial abilities (Adams, 2009; Getz & Levin, 
2017; Gunzler, Schoenberg, Riley, Walter, & Maciuna, 2011; Hirano, Shinotoh, & 
Eidelberg, 2012).   
In recent years, research has demonstrated a need to classify patients with PD who 
have cognitive impairments, but do not have the functional impairments required for a 
diagnosis of dementia.  Approximately 25% of patients with PD have mild cognitive 
impairment (MCI) (Weintraub & Mamikonyan, 2019).  Various criteria for PD-MCI have 
been proposed in the literature making it difficult to compare studies.  Recently, the 
movement disorders society (MDS) commissioned a task-force to define suggested 
criteria to be used for PD-MCI (Litvan et al., 2012).  PD-MCI is characterized by an 
insidious decline in cognitive abilities caused primarily by the underlying disease 
process.  The cognitive decline may be reported by either the patient or an informant, or 
observed by the clinician.  These subjective cognitive concerns must be accompanied by 
objective evidence of cognitive deficits on neuropsychological testing.  Finally, the 
cognitive deficits in PD-MCI are not sufficient enough to interfere with functional 
3 
independence (Litvan et al., 2012).  The MDS criteria includes guidelines for level 1 and 
level II diagnostic categories.  The Level 1 category allows for PD-MCI to be diagnosed 
based on an abbreviated cognitive assessment (e.g., a scale measuring global cognition 
validated for use in PD or a limited battery of neuropsychological tests) as 
comprehensive testing may not always be practical or available; however this method 
provides less diagnostic certainty.   When using a limited neuropsychological battery, 
Level I criteria requires impairment in at least two tests.   Level II criteria requires 
comprehensive neuropsychological testing that includes at least two tests in the domains 
of attention/working memory, executive, language, memory, and visuospatial functions.  
Impairment must be present on at least two tests within a single domain or across 
different cognitive domains.  Impairment may be defined as 1-2 standard deviations (SD) 
below normative data, a significant decline in serial testing, or a significant decline from 
estimated premorbid levels.  Level II criteria also allow for subtype classifications (i.e., 
single or multiple domain) and require specification of the affected domains (i.e., 
memory, visuospatial) (Litvan et al., 2012).  MCI has prognostic value in predicting 
conversion to dementia (Litvan et al., 2012; Williams-Gray et al., 2013), which occurs in 
approximately 80% of patients with PD (Aarsland, Brown, Larsen, & Ballard, 2005; 
Litvan et al., 2012; Weintraub & Mamikonyan, 2019). 
1.3 Neuropsychiatric Disorders in PD 
The most common psychiatric feature in PD is depression, with clinically 
significant depressive symptoms occurring in approximately 30% of patients with PD  
(Reijnders, Ehrt, Weber, Aarsland & Leentjens, 2008).  Anxiety, apathy, and impulse 
control disorders are common as well (Aarsland, Marsh, & Schrag, 2009).  The 
 4 
 
pathophysiological bases of both cognitive and affective symptoms are complex and 
likely involve dopaminergic, serotonergic, and noradrenergic systems (Aarsland, Marsh, 
& Schrag, 2009; Halliday et al., 2014).  Furthermore, these affective symptoms may 
impair cognition and adversely affect neuropsychological performance (Adams, 2009; 
Getz & Levin, 2017; Litvan et al., 2012).  In addition, psychiatric symptoms can predate 
the motor symptoms of the disease by several years (Aarsland, Marsh, & Schrag, 2009).  
Finally, autonomic nervous system dysfunction is also prevalent in PD and can manifest 
as difficulty swallowing, constipation, orthostatic hypotension, urinary leakage, or sexual 
dysfunction (Gunzler, Schoenberg, Riley, Walter, & Maciuna, 2011; Jankovic, 2008).   
1.4 The Basal Ganglia 
 
The neuropathology of PD is associated with dysfunction of the basal ganglia.  
The basal ganglia include the globus pallidi, caudate nuclei, putamina, substantia nigras, 
and the subthalamic nuclei (see Figure 1.1).  The nuclei of the basal ganglia are known to 
initiate and control motor movement and are specifically important for the fine-tuning of 
motor movement.  When these areas are damaged, motor dysfunction such as tremor, 
rigidity, and dyskinesias can emerge (Alexander, DeLong, & Strick, 1986; Gunzler et al., 
2011; Halliday et al., 2014; Jankovic, 2008). 
The basal ganglia are heavily connected to the frontal lobes and communication 
between the cortex and the basal ganglia is facilitated by multiple (closed) parallel 
cortico-striato-thalamo-cortical (CSTC) loops (see Figure 2).  Each circuit originates in 
specific regions of the cerebral cortex (e.g., motor, oculomotor, dorsolateral, 
orbitofrontal, and anterior cingulate), traverse specific regions of the basal ganglia (e.g., 
striatum, pallidum, and substantia nigra) and thalamus, and project back to one of the 
5 
cortical areas, thereby completing the closed loop (Alexander, DeLong, & Strick, 1986).  
These loops are divided into two motor (i.e., motor and oculomotor) and three 
cognitive/behavioral (i.e., dorsolateral, orbitofrontal, and anterior cingulate) domains 
(Alexander, DeLong, & Strick, 1986; Obeso et al., 2014).  Although each CSTC circuit 
constitutes a closed loop, open loop elements are incorporated into the connectivity as 
well, including afferent and efferent projections to and from other cortical areas (e.g., 
temporal and parietal lobes) and thalamic and amygdalar nuclei (Bonelli & Cummings, 
2007). 
 6 
 
Figure 1.1 Cortico-striato-thalamo-cortical loops.  
Diagram of the motor, associative (cognitive) and limbic cortico-striatal circuits.  The 
loops connect the cortex to the basal ganglia.  Put = putamen; GPe = globus pallidus 
externa; GPi = globus pallidus interna; STN = subthalamic nucleus; Cn = Caudate 
nucleus. (Lapidus, Stern, Berlin, & Goodman, 2014). 
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Each CSTC loop can be further divided into two pathways: the direct pathway 
which increases movement and the indirect pathway which inhibits movement.  In the 
direct pathway, the motor cortex and substantia nigra pars compacta (SNc) excite the 
striatum via the D1 dopamine receptor.  When the striatum is excited, it sends inhibitory 
signals (GABA) to the globus pallidus interna (GPi) and the substantia nigra pars 
reticulata (SNr).  Once the GPi and SNr are inhibited, the thalamus is free to send 
excitatory signals (glutamate) to the motor cortex, thereby increasing movement.  In the 
indirect pathway, the motor cortex excites the striatum while the SNc inhibits the striatum 
via the D2 dopamine receptor.  This in turn inhibits the globus pallidus externa (GPe).  
Once the GPe is inhibited, there is less inhibition of the subthalamic nucleus (STN), 
which leads to excitation of the GPi.  The GPi then sends inhibitory signals to the 
thalamus, leading to less excitation of the motor cortex and therefore less movement.  
The direct and indirect pathways create balance between competing excitatory and 
inhibitory impulses; imbalance between these pathways results in dysfunction (Gunzler, 
Schoenberg, Riley, Walter, & Maciuna, 2011).  Recent research has demonstrated that 
several cortical areas (e.g., the motor area, premotor cortex, anterior cingulate cortex, 
dorsolateral prefrontal cortex, etc.) have excitatory projections directly to the STN, 
creating an additional route beyond the direct and indirect pathways.  These pathways are 
collectively known as the hyperdirect pathway and serve as the quickest route for access 
to output pathways (Jahanshahi, Obeso, Rothwell, & Obeso, 2015) 
1.5 Dopamine Depletion and Dysfunction of Frontostriatal Loops 
Although the basal ganglia loops were originally studied within the motor system, 
we now know the important role that the basal ganglia play in regulating cognition.  The 
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primary CSTC pathway of interest for this study is the pathway that connects the 
prefrontal cortex and the striatum.  The dorsolateral prefrontal cortex (DLPFC) loop 
originates in the prefrontal cortex (Brodmann’s areas 9,10, and 46) and projects to the 
dorsolateral head of the caudate nucleus (see Figure 1.2).  The caudate then in turn 
projects the GPi/SNr via the direct pathway.  The indirect pathway sends fibers to the 
GPe which projects to the STN and then terminates in the GPi/SNr.  Output from the 
basal ganglia is then projected to the thalamus, which in turn projects back to the 
dorsolateral prefrontal cortex. Disruptions in the dopaminergic projections along this 
pathway (i.e., loss of dopaminergic neurons in the SNc which projects to the striatum) 
can lead to problems with EF (e.g., organization, mental flexibility, and problem solving) 
(Getz & Levin, 2017; Jankovic, 2008; Poletti & Bonucelli, 2013). 
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Figure 1.2. Coronal view of the brain showing the main basal ganglia nuclei and related 
structures.  
Striatum = caudate nucleus and putamen; GPe = globus pallidus externa; GPi = globus 
pallidus interna; STN = subthalamic nucleus; SNc = substantia nigra pars compacta; SNr 
= substantia nigra reticulate (Obeso, Rodriguez-Oraz, Stamelou, Bhatia, & Burn, 2014) 
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Because of the spatiotemporal progression of the dopamine depletion, affecting 
the dorsal striatum first, tasks associated with this region (e.g. set shifting and planning) 
may improve with dopamine replacement therapy.  In contrast, functions such as reversal 
and implicit learning which are associated with the ventral striatum (i.e., ventral caudate, 
putamen, and nucleus accumbens) may worsen due to “overdosing” these less dopamine 
depleted brain regions (Cools, 2006; Getz & Levin, 2017; Poletti & Bonucelli, 2013).  
Thus, the relationship between dopamine and performance follows an inverted U-shaped 
function, such that both too little and too much dopamine can impair performance 
depending on the type of task and the brain region recruited.  Furthermore, different 
individuals may have different baseline levels of dopamine and may demonstrate 
differential sensitivity to the positive and negative effects of dopamine (Cools, 2006; 
Cools & D’Esposito, 2011).  This individual variation may reflect an individual’s 
position on the hypothetical inverted U-shaped curve (Cools, 2006). 
Dopamine also plays a role in regulating affect.  Dopaminergic disruptions in the 
anterior cingulate pathway can lead to problems with motivation and apathy (Leisman, 
Melillo, & Carrick, 2013).   Apathy occurs in approximately 40% of patients with PD and 
can occur independently of depression, although overlap is common (Weintraub & 
Mamikonyan, 2019).    Dysfunction of the orbitofrontal circuit and lower striatal 
dopamine transporter (DaT) levels can result in behavioral disinhibition in the form of 
impulse control disorders (ICDs).  Impulse control disorders (ICDs) are common 
neuropsychiatric disorders in PD with a prevalence of 14-43% (Smith, Xie, & Weintraub, 
2014).  ICDs can develop following the initiation of dopamine replacement therapy 
(DRT), particularly with the use of D2- receptor selective dopamine agonists (Smith, Xie, 
11 
& Weintraub, 2014; Vriend et al., 2014; Voon et al., 2014).  The primary ICDs in PD are 
compulsive gambling, eating, buying, and sexual behavior; these behaviors are performed 
repetitively, excessively, and compulsively and can interfere with daily functioning 
(Weintraub, David, Evans, Grant & Stacy, 2015).  Therefore, the basal ganglia has 
influence on a broad range of behavior, contributing to the heterogeneous nature of 
symptom presentation in PD.   
1.6 Dopamine Transporter Imaging 
The diagnosis of PD formerly relied solely on the clinical exam; however, 
establishing the cause of PD can be challenging, especially in the early stages of the 
disease (Ravina et al., 2012).  Pathological studies have documented that approximately 
20-25% of clinically diagnosed cases of idiopathic PD are found to have alternative 
diseases at autopsy, with most misdiagnosed cases having Progressive Supranuclear 
Palsy (PSP), Multiple Systems Atrophy (MSA), Alzheimer’s Disease (AD), or vascular 
parkinsonism (Adler et al., 2014; Hughes, Daniel, Kilford, & Lee, 1992).  Early and 
accurate diagnoses in patients with PD and other parkinsonism syndromes is important to 
avoid unnecessary treatments associated with financial costs and side effects.  
Dopaminergic dysfunction can be visualized using a molecular imaging technique 
called the DaTscan, which measures the amount of DaT available in the striatum.  DaTs 
are presynaptic proteins located on the membrane of dopaminergic neuron terminals.  
During excitation, their function is to transport dopamine out of the synaptic cleft and 
back into the presynaptic nerve endings for either storage or degradation (Benamer et al., 
2002; Djang et al., 2012).  The DaTscan uses a dopamine transporter radioligand (i.e., 
123-I-Ioflupane) along with single photon emission computed tomography (SPECT) to 
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visualize the distribution of dopamine within the striatum.  123-I-Ioflupane (DaTscan) is 
a cocaine analogue substance that is injected intravenously, with imaging enabled 3-6 
hours after administration.  123-I-Ioflupane binds to the dopamine transporter and the 
reduction of which correlates with loss of dopamine (Cummings et al., 2011).  
The DaTscan was approved by the European Medicine Agency in 2000 and by 
the Food and Drug Administration in the United States in 2011 for the clinical use of in 
vivo diagnostic imaging of suspected parkinsonian syndromes (Bajaj, Hauser, & 
Grachev, 2013).   The DaTscan can be used in patients with clinically uncertain 
parkinsonism in order to help differentiate degenerative parkinsonian syndromes (e.g., 
PD, MSA, PSP, and Corticobasal Degeneration) from disorders that are not associated 
with a striatal dopaminergic deficit (e.g., essential tremor and drug induced, vascular, or 
psychogenic parkinsonism) (Bajaj, Hauser, & Grachev, 2013; Cummings et al., 2011; 
Djang et al., 2012).  
The DaTscan has demonstrated excellent sensitivity and specificity (Bajaj, 
Birchall, & Jones, 2012; Suwijn et al., 2015).  A study of 743 DaTscan cases performed 
at the United Kingdom National Centre of Excellence for PD over a 9-year period found 
a sensitivity of 99.4% and specificity of 98.6% when compared to clinical diagnosis 
(Bajaj, Birchall, & Jones, 2012).  A recent systematic review of eight DaT SPECT studies 
using several different radiotracers found that the sensitivity and specificity of DaT 
SPECT to detect nigrostriatal cell loss was 98% (Suwijn et al., 2015).  Certain 
medications (e.g., anticholinergics, bupropion, radafaxine, and mazindol) and drugs of 
abuse (e.g., amphetamines, and modafinil) are contraindicated with the scan as they bind 
to the DaT with high affinity, potentially interfering with the DaTscan.  Antiparkinsonian 
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drugs including levodopa, dopamine agonists, monoamine oxidase-B inhibitors, and 
catchol-O-methyl transferase inhibitors do not interfere with the DaTscan and do not 
need to be withdrawn prior to scanning (Booij & Kemp, 2008).  
1.6.1 Visual Interpretation and Quantitative Analysis 
DaTscan results can be classified as normal or abnormal through visual 
interpretation of the striatum, specifically by looking at the shape and symmetry of the 
striata and degree of reduction (Park, 2012).  A normal DaTscan (such as those typically 
seen in patients with essential tremor) looks like two symmetric crescent-shaped areas of 
radioligand uptake in the striatum in both hemispheres.  An abnormal DaTscan shows 
asymmetric or bilateral symmetric decrease in the size or color intensity of the 
radioligand in the striatum (Park, 2012; Waln et al., 2015) (see Figure 1.3).  The side with 
relatively lower uptake generally matches contralaterally to the clinically more affected 
side (Djang et al., 2012; Park, 2012).  Several studies have yielded excellent results with 
visual interpretation only (Benamer et al 2000; Catafau & Tolosa 2004; Tissingh et al., 
1998, Marshall et al 2009).  Imaging results can also be analyzed using 
semiquantification methods, during which binding ratios are calculated by comparing 
activity in the striatum with activity in an area of low DaT concentration, usually the 
occipital lobe (Park 2012; Djang et al 2012). Semiquantification can be done manually or 
by using automated software (Djang et al., 2012) 
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Figure 1.3. Normal and abnormal DaTscans. (Cummings et al., 2011) 
15 
1.7 Review of Prior Dopamine Neuroimaging Studies 
Dopamine transporter availability in the brain can be investigated using different 
radioligands (e.g., 123-I-FP-CIT, 18F-FP-CIT, 99mTc-TRODAT, etc.) with SPECT or 
positron emission tomography (PET) imaging.  SPECT scans are much more available 
and widely used compared to PET scans, however SPECT scans have lower image 
resolution (Cummings et al., 2011; Djang et al., 2012). Studies investigating the 
relationship between DaT availability and cognition have most prominently been 
characterized by significant associations between dopamine and EF (Chung et al., 2018; 
Cropley, Fujita, Innis & Nathan, 2008; Duchesne, Soucy, Masson, Chouinard & Bedard, 
2002; Muller, Wachter, Barthel, Reuter, & von Cramon, 2000; Nobili et al., 2009; 
Pellechia et al., 2015; Pollito et al., 2012; Rinne et al., 2000; Siepel et al., 2014).  A study 
by Duchesne and colleagues found reduced DaT binding in the left striatum was 
associated with deficits in a simultaneous processing task in 10 patients with PD; 
however, this relationship disappeared when patients were tested on their dopaminergic 
medication  (Duchesne, Soucy, Masson, Chouinard & Bedard, 2002).  A similar 
observation was found in a study of 20 PD patients in which DaT availability in both the 
caudate and putamen were significantly associated with set-shifting, cognitive flexibility, 
and working memory (Muller, Wachter, Barthel, Reuter, & von Cramon, 2000).  
However, all of the associations disappeared after patients in the early stages of the 
disease (i.e., Hoehn and Yahr stage < 2) were excluded, suggesting that disease severity 
could have affected their results (Muller, Wachter, Barthel, Reuter, & von Cramon, 
2000).  Another study investigated striatal dopamine in 26 patients with PD using 
fluorodopa (i.e., FDOPA) PET scans.  FDOPA is another measure of presynaptic 
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dopamine commonly used with PET scans, however, it is also sensitive to noradrenergic 
and serotonergic neurons, thus it does not solely reflect the activity of dopamine (Cropley 
et al., 2008; Rinne et al., 2000).  This study found that reduced FDOPA uptake in the 
caudate correlated with impaired working memory, attention, and verbal fluency; 
however, this study also consisted of six patients with dementia, which likely confounded 
the results (Rinne et al., 2000).   
Pollito and colleagues (2012) examined both DaT binding and brain glucose 
metabolism using 18F-fluorodeoxyglucose (FDG) PET in 18 drug-naïve patients with 
PD.  The researchers found that impaired letter fluency was significantly associated with 
reduced DaT in the caudate nucleus; furthermore, lower brain glucose metabolism in the 
DLPFC, orbitofrontal cortex, and the anterior cingulate cortex was associated with worse 
performance on letter fluency.  Nobili and colleagues (2010) compared 30 de novo PD 
patients and 15 patients with essential tremor (ET) and found that DaT availability in the 
caudate was positively associated with EF.  Conversely, there were no significant 
correlations between DaT and cognition in the ET control group (Nobili et al., 2010).  
One study found an association between FDOPA in the putamen and the number of 
categories achieved on the WCST (Cropley, Fujita, Innis & Nathan, 2008).   In contrast 
to the above studies, other studies have failed to find significant associations between 
DaT availability in the striatum and EF (Jokinen et al., 2010; Kubler, Schroll, Buchert 
&Kuhn, 2017). 
A few studies have compared DaT imaging in PD patients with versus without 
MCI.  A study comparing 19 patients with PD and 15 with PD-MCI found lower caudate 
and putamen DaT availability was associated with lower scores on the Frontal 
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Assessment Battery (FAB), lower DaT in the caudate was related to lower scores on 
Trailmaking B minus Trailmaking A (i.e., Trails B minus A), and lower DaT availability 
in the caudate and putamen were associated with lower scores on the Rey-Osterrieth 
Copy Figure test (ROCF) in patients with PD-MCI (Pellechia et al., 2015).  There were 
no significant correlations found between neuropsychological scores and DaT imaging in 
PD patients without MCI (Pellechia et al., 2015).  Chung et al. (2018) found DaT 
availability in the caudate nucleus was positively associated with attention/working 
memory, EF, and visuospatial function in a large sample of drug naïve PD patients with 
and without MCI.  Additional associations were found between attention/working 
memory, EF, language and visuospatial function and DaT binding in the ventral striatum.  
Finally, a recent, large (N =339), multicenter study using patients from the Parkinson’s 
Progression Markers Initiative (PPMI) found small but significant associations between 
DaT availability and verbal memory and attention/executive functioning; however, after 
adjusting for age none of the relationships were significant.  Additionally, DaT binding 
mediated the EF deficit in PD, and age moderated this effect such that the mediation 
effect was stronger for younger patients than in older.  The authors suggested that this 
finding indicated that cognition in the older adults of their sample was likely influenced 
by other neurotransmitters or structural changes (Siepel et al., 2014).  
There is less data examining the extent that DaT availability contributes to 
cognitive domains outside of EF. A study by Jokinen et al. (2010) found that caudate 
FDOPA uptake correlated with verbal and visual memory performance in 19 patients 
with PD.  This study also found that the PD patients had more atrophy in the 
hippocampus and prefrontal cortex compared to controls through volumetric 
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neuroimaging analysis, which may have partially explained their memory findings.  
Muller and colleagues (2000) also found significant associations between DaT 
availability in the striatum and verbal memory.  A few studies have also found significant 
associations between DaT availability in the striatum and performance on the Rey-
Osterrieth Copy Figure test (Chung et al, 2018, Pellechia et al., 2015), however the motor 
component of this measure may have confounded these results. 
In sum, the literature thus far has found significant relationships between the 
striatal DaT availabilty and EF, although some studies have not (Jokinen et al., 2010; 
Kubler, Schroll, Buchert & Kuhn, 2017).  Fewer studies have found relationships 
between DaT availability and verbal (Jokinen et al., 2010; Muller et al., 2000) and visual 
memory (Jokinen et al., 2010) as well as visuospatial functioning (Chung et al, 2018, 
Pellechia et al., 2015).  Some studies found cognition correlated with DaT availability 
solely in the caudate (Pollito et al., 2012; Nobili et al., 2010, Pellechia et al., 2015; Rinne 
et al., 2000), while DaT availability in both the caudate and putamen correlated with 
cognition in other studies  (Chung et al., 2018; Duchesne, Soucy, Masson, Chouinard & 
Bedard, 2002; Muller et al., 2000; Siepel et al 2014).  
1.7.1 Limitations of Prior Studies 
There are several methodological issues that should be considered when 
interpreting the results of prior studies.  First, most of the previous studies included small 
and heterogeneous samples, including patients at different stages of the disease and 
patients both on and off dopaminergic medication.  Furthermore, the neurocognitive 
batteries utilized in the majority of these studies have been fairly limited and could 
potentially underestimate the relationship between DaT and cognition, particularly in 
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domains outside of EF.  Although dopamine systems are mainly involved in prefrontal 
executive functions, other cognitive domains have to be investigated from this 
perspective.  Additionally, various EF measures assess different aspects of the executive 
functioning process, and thus may be differentially relatedly to dopaminergic activity.  
Utilization of a broader neurocognitive battery, including additional EF tests, is 
warranted to fully test these relationships.   Finally, differences in the spatial and 
temporal resolution of PET vs. SPECT scanners, the use of different radioligands, and 
variability in the striatal subregions analyzed likely also contribute to the inconsistencies 
across studies.  
1.8 Purpose of the Present Study 
As described above, studies have looked at the relationship between DaT striatal 
availability and cognition, however sample sizes have been small and heterogeneous 
along with fairly limited neurocognitive batteries.  The present study utilized a 
comprehensive neuropsychological battery assessing multiple domains (e.g., verbal and 
visual memory, language, EF, processing speed, and visuospatial).  Furthermore, given 
the known role of dopaminergic dysfunction on EF abilities, more tests measuring EF 
were included in the present study compared to prior studies.  The present study 
retrospectively examined the relationship between striatal DaT availability using SPECT 
and cognitive data within a consecutive series of PD patients.  Using these data, we can 
understand the relationship more specifically between measurable dopamine availability 
in the brain and changes in reasoning, memory, decision-making, and affect. Some of 
these relationships will teach us about the direct effects of Parkinson-induced changes in 
brain structure and function that can be used for other critical areas, such as new 
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treatment targeting.	  Based on the previous literature the following hypotheses were 
tested: 
1. Study Aim 1: Investigate the pattern of cognitive impairment in patients
with PD compared to age and education matched controls.
a. Hypothesis 1: Given, the role of striatal dopaminergic deficits in
cognition, we predicted that the PD group would demonstrate
worse scores on measures of attention, executive functioning,
learning, and memory when compared to age and education
matched controls.
i. Power analysis: Based on a power analysis, a sample size
of 21 PD patients and 21 controls provided an achieved
power of  0.72 to detect a large effect (d = 0.8).
2. Study Aim 2: Examine the relationship between cognition and striatal DaT
availability in patients with PD at different striatal regions of interest (e.g.,
left and right striatum, left and right caudate nucleus, and left and right
putamen)
a. Hypothesis 2: We expected DaT availability in the striatum to
correlate with measures of executive functioning, learning, and
memory.  Furthermore, we expected moderate to strong positive
correlations between executive functioning measures and DaT
availability in the caudate nucleus, specifically.
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i. Power analysis: Based on a power analysis, the sample size
of 21 PD patients provided an achieved power of 0.71 to
detect a large effect (r = .50).
 METHOD 
2.1 Participants 
The present study was a retrospective chart review.  The data was obtained from a 
movement disorders clinical database at the Norton Neuroscience Institute Nuclear 
Medicine Department in Louisville, Kentucky.  All subjects in the PD group received a 
diagnosis of idiopathic PD by a movement disorders neurologist. The patients without 
dopaminergic deficit on DaTscan were chosen for the comparison group in order to 
highlight the differences in cognition directly resulting from differences in DaT 
availability in the basal ganglia.  Twelve of the control participants had a diagnosis of 
ET, a non-neurodegenerative disorder typically associated with a normal DaTscan.  
Exclusion criteria for both groups included dementia, history of major stroke(s), 
structural lesions, chronic use of antipsychotics or neuroleptics, and major psychiatric 
disorders.  We did not exclude for depression or anxiety in the PD group because PD 
patients commonly report such symptoms.  
2.2 Procedure 
2.2.1 DaTscan 
 All subjects received an intravenous injection of 3-5 millicurie (mCi) of 123-I-
Ioflupane after oral administration of a thyroid-blocking agent (Lugols Solution) one 
hour prior to the scan. Patients were instructed to stop taking drugs that may alter the 
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tracer binding (e.g., amphetamines, methylphenidate, ephedrine, phentermine, bupropion, 
fentanyl, and some anesthetics) for at least 5 half lives.  SPECT imaging was conducted 
3-6 hours post-injection of the radiotracer.  Imaging lasted approximately 30-40 minutes.  
A gamma camera fitted with high-resolution collimators and set to a photo peak of 159 
keV with a + 10% energy window was utilized for SPECT imaging.   Images were 
acquired using a 128 x 128 image matrix (pixel size between 3.5 and 4.5 millimeters) and 
reconstructed using a Butterworth filter.  Images were corrected for attenuation using 
Chang’s algorithm.  Expert readers in the nuclear medicine department at Norton 
Neuroscience Institute performed visual interpretation of the DaTscan.  Scans were read 
clinically as either showing evidence of DaT deficit (i.e.. abnormal) or not showing 
evidence of dopamine transporter deficit (i.e., normal).   
Basal ganglia regions of interest (ROIs) were generated using the MIM 
Neuroimaging software.   This software uses an anatomic atlas (i.e., MIM DaTscan atlas) 
that was created by defining volumes of interest on 10 high resolution T1 weighted MRI 
scans.  Each of the MRI scans were then registered to a template space using their co-
registered SPECT scans.  Manual realignments were made when necessary to adjust the 
generated ROI to the boundaries of the respective DaTscan. Anatomic interrater 
reliability across two raters was excellent ICC = 0.98, 95% CI [0.96-0.99].  Mean DaT 
counts for each striatal subregion in both hemispheres were generated by the MIM Neuro 
software and used for analyses. 
2.2.2 Neuropsychological Assessment 
Raw test scores were standardized into z-scores based on demographically 
published norms.  To reduce the number of analyses, individual test z-scores were then 
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averaged into z-score composites determined a priori.  The composite groupings were 
based on the cognitive domains discussed within the clinical neuropsychological 
literature (Lezak, Howieson, Bigler, & Tranel, 2012).  Due to the large number of EF 
tests which tapped different aspects of EF, the EF composite was split into subdomains 
rather than utilizing a unitary EF composite.  Executive functions are separable and 
different executive functions contribute differently to various complex executive tasks 
(Lezak, Howieson, Bigler, & Tranel, 2012).  EF measures were subject to a factor 
analysis by principal components using an orthogonal (Varimax) rotation.  Factor 
analysis confirmed a 5-factor structure accounting for 93.25% of the total variance in EF.  
The first factor (problem solving/set-shifting) accounted for 25.84% of the variance.  The 
second factor (inhibition) accounted for 21.30% of the variance.  Verbal fluency 
accounted for 17.18% of the variance.  The final two factors, mental flexibility and 
abstract reasoning, accounted for 15.85 and 13.08% of the variance, respectively. 
The verbal memory domain consisted of the Hopkins Verbal Learning Test-
Revised (Trials 1-3 and delayed recall) and the immediate and delayed recall scores from 
the   Neuropsychological Assessment Battery (NAB) List Learning test.  Visual memory 
was assessed using the NAB Shape Learning test (immediate and delayed recall).  
Language measures included the Boston Naming Test (BNT) and NAB Naming.  
Visuospatial functioning was assessed using the Benton Judgment of Line Orientation 
(JLO) test.  Processing speed was measured using Oral Trails A.  EF was divided into 5 
subdomains: mental flexibility (Oral Trails B), inhibition (Delis-Kaplan Executive 
Functioning System Color Word Interference Test (D-KEFS) Conditions 3 and 4), verbal 
fluency (Controlled Oral Word Association Test (COWAT) and Animals), abstract 
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reasoning (Wechsler Adult Intelligence Test- Fourth Edition (WAIS-IV) Similarities 
subtest), and problem solving/set-shifting (Wisconsin Card Sorting Test (WCST) total 
errors and perseverative errors).  Affective measures included the Apathy Evaluation 
Scale (AES) and the Barratt Impulsiveness Scale (BIS). 
2.3 Measures 
2.3.1 Descriptive Measures 
2.3.1.1 Demographic and Clinical Measures 
Demographic information was extracted from each patient’s medical record (e.g., age, 
education, estimated premorbid IQ, gender, and ethnicity).  Additionally, clinical 
measures of disease duration, levodopa equivalent daily dosage (LEDD), non-
dopaminergic medications, and modified Hoehn and Yahr (HY) stage were also collected 
for each individual.  The modified HY scale is a measure of disease severity in PD and 
ranges from 1-5, with higher stages correlating with neuroimaging studies of 
dopaminergic loss (Goetz et al., 2004).   
2.3.2 Neuropsychological Measures 
2.3.2.1 Hopkins Verbal Learning Test-Revised 
The HVLT-R (HVLT-R; Brandt & Benedict, 2001) is a task of verbal learning and 
memory.  The task consists of a 12-item word list presented 3 times in the same order, 
with a test of recall after each trial.  The measure also includes a test of delayed recall and 
recognition.  The test has shown evidence of convergent validity with other measures of 
verbal memory, such as the CVLT-II.  The measure is sensitive to cognitive deficits 
associated with a variety of neurological conditions (e.g., dementia, traumatic brain 
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injury, mood disorders, and substance abuse).  (Lezak, Howeison, Bigler, & Tranel, 
2012; Strauss, Shermann & Spreen, 2006). 
2.3.2.2 NAB List Learning 
The NAB List Learning (Stern & White, 2003) subtest assesses verbal learning and 
memory.  The measure consists of a 12-item word list presented across three trials, 
followed by an interference list, short and long delayed free recall, and forced-choice 
recognition (Strauss, Shermann & Spreen, 2006).  NAB List Learning recall scores have 
demonstrated moderate validity levels with the CVLT-II recall (i.e., r = .43 for immediate 
recall and r = .59 for short delay recall) (Lezak, Howeison, Bigler, & Tranel, 2012). 
2.3.2.3 NAB Shape Learning 
The NAB Shape Learning (Stern & White, 2003)  subtest is a measure of visual learning 
and memory.  The task consists of three learning trials of nine target nonsense shapes.  
Each learning trial is followed by a multiple choice recognition test in which each correct 
target is paired with three foils.  The subtest also consists of a delayed recall and forced-
choice recognition trial (Lezak, Howeison, Bigler, & Tranel, 2012; Strauss, Shermann & 
Spreen, 2006). This task does not require a motor response, thus it is an ideal assessment 
of visual memory in populations who may have compromised motor abilities.  
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2.3.2.4 Boston Naming Test 
The BNT (Kaplan, Goldglass & Weintraub, 1978) is a measure of visual confrontation 
naming ability.  The test consists of 60 line drawings of objects with increasing range of 
difficulty.  Semantic and phonemic cues are provided if necessary and are useful in 
differentiating between problems with storage of information vs. problems with retrieval 
(Lezak, Howeison, Bigler, & Tranel, 2012; Strauss, Shermann & Spreen, 2006).  This 
measure elicits naming impairments in a variety of neurological conditions. (Strauss, 
Shermann & Spreen, 2006).   
2.3.2.5 NAB Naming  
The NAB (Stern & White, 2003)  naming subtest  requires the examinee to name pictured 
items.  Semantic and phonemic cues are provided if necessary. (Strauss, Shermann & 
Spreen, 2006).  Forms 1 and 2 of NAB Naming are moderately correlated (r = .45 and r = 
.50, respectively) with the BNT (Yochim, Kane, & Mueller, 2009). 
2.3.2.6 Benton Judgment of Line Orientation 
The JLO (Benton, Hannay, & Varney, 1975) measures the ability to estimate angular 
relationships between line segments and is a measure of spatial perception and orientation 
(Lezak, Howeison, Bigler, & Tranel, 2012; Strauss, Shermann & Spreen, 2006).  This test 
consists of 30 pairs of angled lines to be matched to display cards.  JLO impairment has 
been reported in a variety of conditions known to affect visuospatial ability including 
left-visual neglect, Parkinson’s Disease, and dementia.  This measure has high internal 
consistency (.90) and demonstrated validity.  In addition, this measure does not require 
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motor skills and demands little to no verbal mediation. (Strauss, Shermann & Spreen, 
2006). 
2.3.2.7 Oral Trailmaking A and B  
 Oral TMT (Ricker & Axelrod, 1994) is an alternative version of the Trailmaking Test A 
& B and is often used with populations with motor deficits or visual impairment.  The 
test is divided into two parts, A and B.  In part A, the examinee is asked to count from 1 
to 25 as quickly as possible.  Part B asks the examinee to alternate between numbers and 
letters aloud up to 13.  Scores are obtained for time and errors.  The correlations between 
the oral and written versions are moderately strong (r= -.68 for part A; r =-.72 for part B) 
(Ricker & Axelrod, 1994).   
2.3.2.8 D-KEFS System Color-Word Interference Test 
The D-KEFS (Delis, Kaplan, & Kramer, 2001) Color-Word Interference Test is a variant 
of the Stroop procedure and measures inhibition of a prepotent response and mental 
flexibility (Strauss, Shermann & Spreen, 2006). The present study utilized Conditions 3 
and 4.  Condition 3 requires the examinee to name the color of the ink in which the words 
are printed.  Condition 4 requires the examinee to switch back and forth between naming 
the dissonant ink colors and reading conflicting words (Strauss, Shermann & Spreen, 
2006).  Internal consistency for Conditions 3 and 4 are adequate. Several studies have 
documented that performance on the D-KEFS is affected by frontal lobe lesions and 
subcortical disease  (Lezak, Howeison, Bigler, & Tranel, 2012). 
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2.3.2.9 Controlled Oral Word Association Test 
 The COWAT (Reitan & Wolfson, 1985)  is a test of phonemic fluency and is part of the 
Expanded Halstead-Reitan Neuropsychological Battery.  The COWAT requires the 
examinee to say as many words as the individual can think of that begin with a specified 
letter in one minute.  The present study used the standard version with the letters F, A, 
and S.  Reduced capacity to generate words on the COWAT is a sensitive indicator or 
brain dysfunction (Lezak, Howeison, Bigler, & Tranel, 2012).  FAS has demonstrated 
high test-retest reliability and correlates highly with other letter sets (e.g., CFL and PRW) 
(Strauss, Shermann & Spreen, 2006).   
2.3.2.10 Animals 
 The “Animals” (Reitan & Wolfson, 1985) category is the most common category used to 
test semantic fluency.  The test requires the examinee to orally produce as many animals 
as possible within one minute.  “Animals” is sensitive to impaired verbal fluency in PD 
(Henry & Crawford, 2004). There is evidence that semantic fluency tests are more useful 
than other neuropsychological tests in the detection of dementia and discrepancies 
between phonemic and category fluency may be useful in distinguishing cortical and 
subcortical dementias ( Lezak, Howeison, Bigler, & Tranel, 2012). 
2.3.2.11 Wechsler Adult Intelligence Scale-Fourth Edition Similarities Subtest 
 (WAIS-IV Similarities) Similarities is a test of verbal concept formation and requires the 
examinee to state how two concepts are alike.  Relatively depressed Similarities scores 
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tend to be associated with left temporal and frontal involvement. (Lezak, Howeison, 
Bigler, & Tranel, 2012). 
 
2.3.2.12 Wisconsin Card Sorting Test 
The WCST (Berg, 1948; Grant & Berg, 1948) measures the ability to form abstract 
concepts, to shift and maintain set, and to utilize feedback.  The WCST is one of the most 
commonly used measures to assess executive functions and provides information 
regarding problem-solving behavior.  The test consists of two decks of 64 response cards, 
which have designs similar to four stimulus cards.  The participant is asked to match each 
of the response cards to one of the four stimulus cards and is given feedback on whether 
he or she is right or wrong each time.  Several component scores provide information 
regarding the examinee’s strategy and problem-solving behavior while completing the 
test (e.g., the number of categories achieved, total errors, perseverative errors, and 
perseverative responses).  Perseverative errors occur either when the examinee continues 
to sort to a previously successful principle or when the participant continues to sort on the 
basis of an initial error.  The perseverative error score may be useful in documenting 
problems in forming concepts, benefitting from correction, and conceptual flexibility.  A 
correct response may also be counted as a perseverative response if it matches a 
previously correct category (Strauss, Shermann & Spreen, 2006).  
 
2.3.2.13 Barratt Impulsiveness Scale 
The BIS (Barratt, 1959) is a 30-item self report measure of impulsivity.  The responses 
load on three 2nd order factors (i.e., Attentional, Motor, and Nonplanning Impulsiveness).  
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Attentional impulsiveness is defined as an inability to focus attention or concentrate, 
motor impulsiveness involves acting without thinking, and non-planning impulsiveness 
refers to a lack of forethought (Stanford et al., 2009).   
2.3.2.14 Apathy Evaluation Scale 
The AES (Marin, Biedrzycki,& Firinciogullari, 1991) is a measure of apathy and assesses 
the behavioral, cognitive, and emotional components associated with goal-directed 
behavior.  A score greater than or equal to 14 indicates the presence of apathy.  There are 
three versions (e.g., self, informant, and clinical).  The present study used the self-report 
version of the AES (Marin, Biedrzycki,& Firinciogullari, 1991).   
2.4 Data Analysis 
Alpha was set at p < .05 for all inferential tests.  Chi-square tests were used to 
determine demographic equivalence between the groups.  The Mann-Whitney U test was 
used in the case of non-normally distributed variables.  Independent samples t-tests were 
used to examine mean-level differences in striatal DaT availability between the PD and 
control group.  The association between neurocognitive measures and DaT availability 
for each ROI was calculated using the Pearson’s product-moment correlation coefficient 
matrix.  Pearson’s correlations were also used to test the association between mean DaT 
availability and affect.  Partial correlations were utilized when appropriate.   
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3 RESULTS 
3.1 Outliers and Normality 
Descriptive statistics revealed that most continuous variables were normally 
distributed.  Examination of skewness and kurtosis statistics, scatterplots, and boxplots 
revealed no problematic outliers or significant skewness or kurtosis for most variables.  
However, there were two neurocognitive variables that exhibited some skewness and 
kurtosis (Oral Trails A and Oral Trails B).  To correct for this, three outliers for the Oral 
Trails A variable and two outliers for the Oral Trails B variable were identified using the 
criteria of > 3 SD from the mean and were not included in the analyses.  Additionally, the 
distribution of HY stages was negatively skewed (Skewness statistic = -1.216, SE = 
.501), thus non-parametric analyses were utilized for this variable. 
3.2 Demographic Characteristics 
As previously noted, participants were identified from archival clinical database 
at Norton Neuroscience Institute.  There were 73 available cases with both a DaTscan 
and neuropsychological testing data, including 34 patients with an abnormal DaTscan and 
43 controls with a normal DaTscan.   Of the 34 participants with an abnormal DaTscan, 
patients were excluded for the following reasons: dementia (n = 11), incomplete 
neuropsychological test data (n =1) and poor effort on neuropsychological testing (n =1).  
Of the 43 participants with a normal DaTscan and neuropsychological test data, 22 
participants were excluded for the following reasons: dementia (n = 8), neurologic 
disorder (n = 4), major psychiatric disorder (n = 6), structural lesion (n =1), chronic 
antipsychotic use (n =2), and incomplete neuropsychological test data (n =1).  This 
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resulted in a final sample size of 42 participants, including 21 participants with PD and 
21 age and education matched controls. 
Demographic characteristics and clinical information of the sample are presented 
in Table 3.1.  PD and control participants did not differ significantly on age, education, 
race, and gender variables.  The overall sample was 90.5% Caucasian and 57.1% percent 
male.  Additionally, 90.5% of the sample was right handed. The PD group had a mean 
age of onset of 61.45 years (SD = 11.83) and mean disease duration of 4.80 years (SD = 
5.08).  HY stage of the PD group ranged from 1-2.5, with a mean of 1.95 (SD =0.44). 
Three PD patients were at HY stage 1 of the disease, 14 were at stage 2, and four at stage 
2.5.   Fifteen of the 21 PD patients were taking dopaminergic medication at the time of 
the DaTscan and 19 at the time of the neuropsychological evaluation. The mean LEDD at 
the time of the DaTscan (M = 978.71; SD = 646.606) was statistically significantly higher 
than the mean LEDD during the neuropsychological evaluation (M= 432.38; SD = 
408.374) (t = 6.94. p = .000). 
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Table 3.1. Descriptive Statistics by Group
 PD   C 
n = 21 n = 21 t or Χ2 p
Age DaTscan M (SD) 66.67 (11.16) 68.43 (8.85) -0.57 0.58 
Age NP M (SD) 67.14 (10.49) 68.29 (8.67) -0.39 0.70 
Education M (SD) 13.71 (2.37) 14.48 (3.09) -0.90 0.38 
Gender % Male 62.0% 52.0% 0.39 0.53 
Race % Caucasian     91% 91% 1.33 0.51 
Age Sx Onset M (SD) 61.45 (11.83) 
Disease Duration M (SD) 4.80 (5.08) 
Hoehn and Yahr M (SD) 1.95 (0.44) 
LEDD DaTscan M (SD) 432.38 (408.374) 
LEDD NP M (SD) 978.71 (646.06) 
Note: PD, Parkinson’s Disease patient group; C, Controls; M, Mean; SD , Standard 
Deviation; NP, Neuropsychology; Sx,  Symptom; LEDD, Levodopa Equivalency Daily 
Dosage 
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3.3 Group Differences in DaT Imaging 
Table 3.2 presents mean group differences for DaT availability in each striatal 
ROI by group.  The left striatum value is a composite of the left caudate nucleus 
putamen, and the right striatum is a composite of the right caudate nucleus and putamen.  
Significant group differences at p < 0.01 level were found in each of the striatal ROIs 
analyzed: left striatum (t= -3.45, p = 0.001), left caudate (t= -2.96, p = 0.005), left 
putamen (t = -3.75, p = 0.001), right striatum (t = -3.33, p = 0.001), right caudate (t = -
2.64, p = 0.012), and right putamen (t = -3.69, p = 0.001).  In all instances the PD group 
had significantly lower mean counts of DaT availability in each striatal ROI.  
Additionally, Table 3.2 shows that group differences in mean counts of DaT at each ROI 
demonstrated large effect sizes (d= 0.81-1.14).  A graphical depiction of the mean group 
differences on DaT availability are presented in Figure 3.1.  Paired sample t tests were 
used to examine laterality differences in mean DaT availability within each group. There 
were no significant differences between DaT availability in the left and right striatum (t 
=-1.96, p = .06), left and right caudate (t =-1.55, p = 0.14), or left and right putamen (t =-
2.21, p = 0.04) in the PD group.  In the control group the left putamen had significantly 
lower mean DaT availability than right putamen (t =-3.26, p = 0.004), despite being 
clinically read as normal.  There were no significant differences between left and right 
striatum (t = -1.74, p = 0.10) and left and right caudate (t = -.013, p =0.99).   
35 
Table 3.2. Group differences in DaT availability 
 PD   C 
n = 21 n = 21 p d
Left striatum M (SD) 23.65 (9.62) 36.41 (13.99) 0.001 1.06** 
Left caudate M (SD) 26.01 (10.55) 38 (15.37) 0.005 0.91** 
Left putamen M (SD) 21.89 (9.50) 35.15 (13.19) 0.001 1.15** 
Right striatum M (SD) 24.54 (10.32) 37.33(14.28) 0.001 1.03** 
Right caudate M (SD) 26.89 (11.26) 38.08 (15.83) 0.012 0.81** 
Right putamen M (SD) 23.41 (9.96) 37.01 (13.68) 0.001 1.14** 
 
fdfd 
    Note: PD, Parkinson’s Disease; C, Control; M, Mean; SD, Standard Deviation 
    ** p < .01 
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Figure 3.1. Bar graph depicting group differences on DaT availability 
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3.4 Group Differences on Cognitive Composites 
Hypothesis 1 aimed to examine group differences on neurocognitive measures 
between the PD group and controls.  There were no statistically significant group 
differences on any of the cognitive composites (Table 3.3).  Both PD and control 
participants mean z-scores were within the normal range, not exceeding 1.5 SD.  The 
mean scores of only two domains across both groups (i.e., verbal memory and processing 
speed) were greater than 1 SD; however as stated previously, group performances were 
statistically comparable on these domains.  Therefore, Hypothesis 1 was not supported in 
that the PD group did not perform statistically worse on measures of executive 
functioning, learning, and memory compared to controls.  
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Table 3.3 Group differences on cognitive composites 
Language 
(z-score) 
 PD 
n = 21 
    C 
n = 21 p d 
M 0.39 0.13 0.34 0.31 
(SD) (0.70) (1.01) 
Verbal Memory 
(z-score) 
M -1.25 -1.02 0.51 0.21 
(SD) (1.15) (1.04) 
Visual Memory 
(z-score) 
M -0.12 -0.32 0.47 0.22 
(SD) (1.01) (1.13) 
Visuospatial 
(z-score) 
M 0.01 -0.01       0.96 0.02 
(SD) (1.13) (1.11) 
Processing Speed 
(z-score) 
M -1.10 -1.37 0.41 0.36 
(SD) (0.67) (1.00) 
Mental Flexibility 
(z-score) 
M 0.10 -0.54 0.66 0.16 
(SD) (0.77) (1.04) 
Inhibition 
(z-score) 
M -0.42 -0.87 0.35 0.34 
(SD) (1.30) (1.36) 
Verbal Fluency 
(z-score) 
M -0.69 -0.76 0.86 0.06 
(SD) (1.18) (0.98) 
Abstract Reasoning 
(z-score) 
M -0.54 -0.51       0.99 0.004 
(SD) (0.74) (0.64) 
Problem Solving/Set-Shifting 
(z-score) 
M -0.52 -0.68 0.67 0.17 
(SD) (0.95) (0.88) 
 Note: M, Mean; SD, Standard Deviation; PD, Parkinson’s Disease; C, Controls; EF, Executive Functioning 
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3.5 DaT and Cognitive Composites: PD Group 
Hypothesis 2 predicted that DaT availability in the striatum would be significantly 
related to performance on measures of executive functioning, learning, and memory.  It 
was further predicted that the association between DaT and executive functioning would 
be strongest in the caudate nucleus.  Table 3.4 provides Pearson’s correlations between 
mean DaT availability and cognitive composites for the PD group only.  Regarding 
executive functioning, there was a strong positive relationship (r =. 55, p = .03), between 
DaT availability in the left caudate and the problem solving/set-shifting composite, such 
that increased DaT availability was associated with better problem solving/set-shifting 
abilities (see Figure 3.2).  Strong relationships (r = .52-.61) were found between DaT 
availability and verbal memory in all striatal ROIs (e.g. left striatum, left caudate, left 
putamen, right striatum, right caudate, and right putamen), such that increased DaT 
availability was associated with stronger verbal memory performance for PD patients. 
The strongest association was between DaT availability in the right caudate and verbal 
memory and is presented in Figure 3.3.  Finally, there were modest to strong positive 
correlations (r = .49-.56) between DaT availability in all ROIs and visuospatial 
functioning, such that higher DaT availability was significantly related to better 
performance on the JLO.   
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Table 3.4 Pearson’s correlations between DaT availability and cognitive composites in 
PD 
EF Composite 1
LS LC                LP RS     RC                RP 
Verbal Memory .548* .543* .518* .594** .611** .578** 
Visual Memory .234 .283 .176 .248 .250 .243 
Language .167 .091 .221 .122 .145 .108 
Visuospatial .551* .511* .541* .521* .562*  .492* 
Processing Speed -.135 -.019 -.222 -.160 -.059 -.214 
Mental Flexibility -.157 -.057 -.226 -.173 -.127 -.196 
Inhibition .336 .358 .289 .344 .404 .306 
Verbal Fluency .011 .156 -.113 -.036 .067 -.091 
Abstract Reasoning .248 .260 .220 .186 .209 .170 
Problem Solving/Set Shifting .490 .549* .390 .512 .510 .506 
Note: LS=Left Striatum; LC= Left Caudate; LP= Left Putamen; RS=Right Striatum; RC= 
Right Caudate; RP= Right Putamen 
* p < .05, ** p < .01
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Figure 3.2.  Scatterplot showing the correlation between problem solving/set-shifting and 
DaT availability in the left caudate region of interest  
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Figure 3.3 Scatterplot showing the correlation between verbal memory and DaT 
availability in the right caudate region of interest  
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Correlations between potential confounding variables (e.g. depression, LEDD, 
disease duration, and HY stage) were examined to determine whether there was a need to 
control for these variables.  HY stage was significantly positively associated with DaT 
availability in all ROIs ( rs= .45-.55) .  Given the significant relationships between HY 
stage and DaT availability, partial correlations were utilized to examine the relationship 
of DaT and cognition while controlling for Hoehn and Yahr stage.  Table 3.5 provides the 
partial correlations for relationships between DaT availability and verbal 
learning/memory, problem solving/set shifting, and visuospatial domains when 
controlling for HY stage within the PD group only.  Partial correlations between DaT 
availability and verbal memory and DaT availability and visuospatial skills were 
generally in the medium to large range (Table 3.5). The correlation between DaT 
availability and problem solving/set shifting was no longer significant after controlling 
for HY stage.  There was no need to statistically control for other suspected confounding 
variables (e.g. depression, LEDD, and disease duration) due to the lack of significant 
relationships.  
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Table 3.5 Partial correlations between DaT availability and cognitive composites 
in PD controlling for Hoehn and Yahr stage 
 
EF 
Composite
1
LS          LC      LP              RS            RC         RP 
Verbal 
Memory 
.479* .373 .461* .528* .534* .454* 
Visuospati
al 
.518* .512* .471* .529* .565* .422 
Problem 
Solving/Set 
Shifting 
.470 .467 .521 .493 .527 .493 
Note:  LS=Left Striatum; LC= Left Caudate; LP= Left Putamen; RS=Right Striatum; 
RC= Right Caudate; RP= Right Putamen  
* p < .05, ** p < .01
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Hypothesis 2 was partially supported such that increased DaT availability was 
significantly associated with better performance on measures of verbal memory and 
problem solving/set shifting as predicted.  The positive association between DaT 
availability and problem solving/set shifting was significant within the caudate nucleus 
specifically, consistent with our hypothesis.  Additionally, the significant associations 
between DaT availability and both verbal memory and visuospatial functioning were 
strongest in the caudate nucleus.  Contrary to our hypothesis, there were not any 
significant relationships between DaT availability and visual memory or other aspects of 
EF (e.g., mental flexibility, inhibition/switching, verbal fluency, and abstract reasoning) 
within the PD group.  
3.6 DaT and Cognitive Composites: Control Group 
Similar to the PD group, large positive relationships (r = .54-.59) were found 
between the verbal memory composite and several ROIs (e.g. left striatum, left caudate, 
left putamen, and right striatum) (Table 3.6).  Additionally, DaT availability in the 
control group was significantly related to some aspects of EF.  Strong positive 
relationships (r= .68-.72) were found between DaT availability in all striatal ROIs and the 
inhibition composite, such that higher levels of DaT availability were associated with 
better ability to inhibit a prepotent response.  Increased DaT in the left caudate and right 
putamen were significantly associated with better problem solving/set shifting (r = .61 
and .60, respectively).  In sum, in age and education matched controls there were strong 
positive correlations found between DaT availability and verbal memory and subdomains 
of EF.  
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Table 3.6 Pearson’s correlations between DaT availability and cognitive composites in 
Controls 
 
EF Composite
1
 LS      LC       LP       RS RC         RP 
Verbal 
Memory 
.573*
*
.543* .589** .585** .580 -.329 
Visual 
Memory 
.185 .232 .133 .131 .194 .096 
Language .366 .414 .295 .386 .448 .346 
Visuospatial .256 .250 .258 .272 .226  .295 
Processing 
Speed 
.401 .407 .391 .426 .422 .425 
Mental 
Flexibility
.396 .371 .412 .390 .340 .415 
Inhibition  .702
** 
.681* .711** .708** .687
** 
.715** 
Verbal 
Fluency
.325 .314 .332 .324 .343 .318 
Abstract 
Reasoning 
.285 .249 .313 .279 .218 .312 
Problem 
Solving/Set 
Shifting 
.590 .606* .568 .602 .593 .604* 
Note: LS=Left Striatum; LC= Left Caudate; LP= Left Putamen; RS=Right 
Striatum; RC= Right Caudate; RP= Right Putamen  
* p < .05, ** p < .01
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3.7 Exploratory analyses: Correlations between DaT and Affect 
Additional exploratory analyses were conducted to examine the relationship 
between DaT availability and symptoms of apathy and impulsivity.  Table 3.7 presents 
group differences on the AES and BIS.  There were no statistically significant group 
differences on self-reported symptoms of apathy and impulsivity between the PD group 
and controls.  Table 3.8 presents Pearson’s correlations between DaT availability and 
affective measures.  In the PD group, there was a strong negative correlation (r =-.62, p = 
.01) between DaT in the left putamen and motor impulsiveness on the BIS, such that 
decreased DaT was associated with greater motor impulsiveness (see Figure 3.4).  
Further, a strong negative correlation was found between mean DaT availability in the 
left striatum (r = -.56, p = .03) and motor impulsiveness (see Figure 3.5).  Given the 
significant relationships between and HY stage and DaT, partial correlations were 
utilized to examine the relationship between DaT and motor impulsiveness while 
controlling for HY stage.  When controlling for HY stage, partial correlations remained 
significant for relationships between DaT and both the left putamen (r = -.56, p =  .04) 
and left striatum (r = -.54, p = .04).  There were no significant associations between DaT 
availability and symptoms of affect within the PD group.  Finally, neither apathy nor 
impulsivity was significantly associated with DaT availability in the control group. 
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Table 3.7 Group differences on affective measures 
AES 
PD 
n = 
14 
C 
n = 
11 
p d 
M 11.27 15.00 0.21 0.51 
(SD) (6.92) (7.79) 
BIS Total 
(z-score) 
M -0.31 -0.01 0.51 0.27 
(SD) (1.27) (0.97) 
BIS Att Imp 
(z-score) 
M -0.36 -0.81 0.52 0.43 
(SD) (1.17) (0.90) 
BIS Motor 
Imp (z-score) 
M -0.24 -0.69 0.26 0.46 
(SD) (1.11) (0.81) 
BIS Nonp 
Imp (z-score) 
M -0.12 0.45 0.23 0.28 
(SD) (1.18) (1.18) 
Note: M, Mean; SD, Standard Deviation; PD, Parkinson’s Disease; C,  
Controls; AES, Apathy Evaluation Scale; BIS Total, Barratt Impulsiveness 
Total Score; BIS Att Imp  
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Table 3.8 Pearson’s correlations between DaT uptake and affective measures in PD 
AES 
LS 
LC LP 
        RS RC         RP 
-
.03
6 
.019 -.099 -.052 -.075 -.037 
BIS Total -
.367
-.309 -.424 -.305 -.339 -.282 
BIS Att Imp -
.191
-.159 -.221 -.151 -.216 -.113 
BIS Motor 
Imp
-
.555
*
-.483 -.622* -.480 -.483 -.473 
BIS Non 
Planning Imp 
-
.26
3 
-.209 -.319 -.218 -.232 -.208 
Note: LS=Left Striatum; LC= Left Caudate; LP= Left Putamen; RS=Right Striatum; 
RC= Right Caudate; RP= Right Putamen; AES, Apathy Evaluation Scale; BIS 
Total, Barratt Impulsiveness Total Score; BIS Att Imp  
* p < .05, ** p < .01
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Figure 3.4  Scatterplot showing the correlation between motor impulsiveness and 
DaTscan availability in the left putamen region of interest  
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Figure 3.5.  Scatterplot showing the correlation between motor impulsiveness and 
DaTscan availability in the left striatum region of interest  
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 DISCUSSION 
4.1 Overview of the Findings
 Although PD is defined classically by motor symptoms, non-motor deficits (e.g., 
cognitive, affective, and autonomic abnormalities) form an important part of the disease.  
Greater understanding about the neuropathology underlying the cognitive and emotional 
sequelae of PD is of the utmost importance in order to potentially enhance treatment 
planning.  The current study aimed to elucidate the relationship between striatal 
dopamine and cognitive functioning in patients with PD using neuroimaging, 
neuropsychological, and psychological methods.  Additional exploratory analyses 
examined the relationship between dopamine and affect (i.e., apathy and impulsivity).  
An innovative aspect of this project was the exploration of these relationships using a 
comprehensive neuropsychological battery that covered multiple cognitive domains, as 
well as assessing the regional effects of DaT availability on cognition in PD.
4.2 Cognition in PD versus Controls
Although the PD group did demonstrate significant reductions of DaT in all 
striatal ROIs compared to controls, this did not translate into reduced neurocognitive 
deficits in the PD group as predicted.  Contrary to our hypothesis, the PD group did not 
demonstrate statistically worse performance on cognitive tasks that are associated with 
frontostriatal dysfunction  (e.g., attention, learning, and EF).  This is inconsistent with 
prior studies that have found deficits on these tasks secondary to loss of dopamine in the 
striatum, which has direct connections to the frontal cortex (Kehagia, Barker, & Robbins, 
2010; Kudlicka, Clare, & Hindle, 2011; Williams-Gray et al., 2013).  One possible 
explanation for this finding is that the majority of the PD patients in our sample were on 
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dopaminergic medication.  Administration of dopaminergic medication may replete 
dopamine deficient circuits, thus in the early stages of the disease, may have a beneficial 
effect on cognitive functions associated with the cortico-striato-thalamo-cortical loop 
(e.g., EF) (Cools, 2006; Cools & D’Esposito, 2011; Poletti & Bonnucelli, 
2013).   Therefore, it is presumed that the normalizing effects of dopaminergic 
medications may have contributed to the overall lack of cognitive impairment findings 
within the PD sample.  Additional studies assessing PD patients off of their medication or 
drug naive patients are warranted.  Furthermore, the PD patients were in the early stages 
of the disease (i.e., disease duration M= 4.8 years), which could have contributed to the 
lack of neuropsychological deficits found in this sample.   Our findings of no statistical 
differences in cognition between PD and controls did converge with one study (Cropley 
et al., 2008), however this study only utilized two neuropsychological measures to assess 
cognition in their groups.  Additionally, a recent study of PD patients without dementia (n 
=143) found that significant caudate nucleus dopaminergic denervation was frequent in 
those with minimal to no cognitive changes (51.1%) (Bohnen et al., 2015), therefore 
illustrating that biochemical and structural change does not always result in cognitive 
deficits or clinical symptoms. 
4.3 Relationships between Dopamine and Cognition: PD
The present study demonstrated that DaT imaging correlates with certain 
measures of cognitive functioning within a sample of PD patients.  A strong positive 
association was found between DaT availability in the left caudate and problem 
solving/set-shifting.  This finding is in agreement with other studies that have 
demonstrated significant associations between DaT availability in the caudate and set-
54 
shifting (Monchi et al., 2001; Rogers et al., 2000), as well as various other aspects of EF 
in patients with PD (Chung et al., 2018; Muller, 2000; Nobili, 2010; Pollito, 2012; 
Pellechia et al., 2015; Rinne, 2000; Siepel et al., 2014).  Set-shifting is defined as the 
ability to change our attention from one response set to another according to the changing 
goals of a task (Provost, Hanganu, & Monchi, 2015). Secondly, there were significant 
strong relationships between DaT in all striatal areas and verbal memory, such that 
greater DaT availability was associated with better verbal memory.  This result is 
consistent with findings from other studies that have found a significant relationship 
between DaT availability in the caudate nucleus and verbal memory (Siepel et al., 2014) 
and significant associations between FDOPA uptake in the caudate and both verbal and 
visual memory (Jokinen et al., 2010).  Memory deficits in PD patients without dementia 
often stem from inefficient learning and organization due to frontostriatal dysfunction 
(Adams, 2009; Getz & Levin, 2017).  Patients with PD have also demonstrated difficulty 
with free recall on memory tasks, but benefit from cues, suggesting that the memory 
problems in PD are sometimes related to impaired executive functioning required for 
memory retrieval (Getz & Levin, 2017).  Thus, the memory findings in our sample may 
be representing a dysexecutive process rather than a pure memory deficit, however due to 
the use of a composite scores we could not examine retention scores explicitly.   
Finally, our study found that DaT availability in the striatum was significantly 
positively related to visuospatial functioning.  This finding is consistent with a recent 
study by Chung and colleagues (2018) who found that DaT availability in the caudate 
was positively associated with visuospatial functioning in a large sample of PD patients 
without dementia (n = 311).   A similar finding was found in a sample of PD patients 
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with MCI, in which reduced DaT availability in the caudate and putamen were associated 
with lower scores on a visuospatial construction task (Pellechia et al., 2015).   Of note, 
both studies used the Rey Complex Figure Copy to assess visuospatial functioning; thus, 
the motor component involved in the task could have confounded their results.  In 
contrast, another large multicenter study consisting of patients from the PPMI, a cohort of 
de novo PD patients, failed to find significant relationships between DaT binding and the 
JOLO (Siepel et al., 2014).  As observed with memory deficits, visuospatial deficits in 
early PD may reflect executive deficits related to frontostriatal dysfunction, rather than a 
pure visuospatial difficulty (Adams, 2009; Getz & Levin, 2017).  Pure visuospatial 
deficits may represent more posterior cortical dysfunction and can predict dementia (Getz 
& Levin, 2017; Kehagia, Barker, & Robbins, 2010; Williams-Gray et al., 2013). 
4.4 Relationships between Dopamine and Cognition: Controls 
 
Similar relationships were found between DaT availability and cognition in age 
and education matched controls.  Specifically, there were significant positive 
relationships between DaT availability in the striatum and performance on measures of 
verbal memory, inhibition, and problem solving/set-shifting.  There are several potential 
explanations for the amount of significant correlations in the control group.  First, 12 
subjects in the control group had a diagnosis of ET.  ET is a non-neurodegenerative 
disorder and is the most common cause of tremor.   ET results in an action or postural 
tremor as opposed to the resting tremor associated with parkinsonism (Gunzler, 
Schoenberg, Riley, Walter,& Maciuna; 2011).  Although ET is typically associated with a 
normal DaTscan, some studies have reported mild striatal dopaminergic deficit in patients 
with ET compared to healthy controls, particularly in the caudate nucleus (Isais et al., 
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2010; Gerasimou et al., 2012; Waln et al., 2015).  Furthermore, some studies have 
reported neuropsychological deficits in patients with ET, particularly in the domains of 
attention, working memory, and EF (Gasparini et al., 2001; Lombardi et al., 2001; 
Troster et al., 2002), which can occur as a result of the cerebello-thalamo-cortical circuit 
dysfunction that occurs with ET (Troster et al., 2002).   
Additionally, there are other confounding variables that are inevitable when 
assessing cognition within an older adult sample.  The presence of cognitive impairment 
increases with age, with EF abilities being among the first to decline  (Aine et al., 2014; 
Zelazo, Craik, & Booth, 2004).   Furthermore, age-related changes in dopamine have also 
been reported, albeit at a slower rate than patients with PD (Kassinen & Rinne, 2002; 
Volkow et al., 1998) Specifically, the availability of D1-like (i.e., D1 and D5) dopamine 
receptors in the striatum decrease at a rate ~7% per decade and D2-like (i.e., D2 ,D3, and 
D4) receptors decrease between 5-10 % per decade in striatal availability (Kassinen & 
Rinne, 2002).  Of note, the DaTscans of all control participants in this study were 
interpreted as having normal striatal uptake.
White matter hyperintensities (WMH) are a common finding in the brains of older 
individuals, and are associated with vascular risk factors (e.g. hypertension, diabetes 
mellitus, and cerebral amyloid angiopathy).  These vascular risk factors have been 
independently associated with cognitive decline of a frontal-subcortical nature initially, 
affecting executive functioning and processing speed in particular (Adams, 2009; Aine et 
al., 2014).  Thus, the increased incidence of vascular risk factors that come with old age 
may cause otherwise “normal” controls to look neuropsychologically similar to other 
subcortical illnesses, such as PD.  Due to limited sample sizes, we did not exclude 
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patients with vascular risk factors, with the exception of major strokes and structural 
lesions.  As such, over half (n =14) of the participants in the control group had evidence 
of cardiovascular disease according to medical record review (i.e., hypertension, 
hyperlipidemia, and diabetes mellitus type 2), which may have confounded the results.  
By including a control group consisting of patients with ET and older adults we are aware 
of the suboptimal “healthy” control group.  However, there are ethical considerations 
when studying radioactive compounds in healthy subjects; as such, control participants in 
neuroimaging studies are often bound by certain constraints.    
Finally, low and/or abnormal neuropsychological test scores are common in 
normative samples, with the frequency increasing with the more tests included in the 
battery.  Additional explanations for subtest scatter within a normative sample may also 
include measurement error, longstanding weaknesses in certain domains of cognitive 
functioning, and other situational factors (e.g., fluctuations in attention, motivation, or 
effort, and fatigue) (Binder, Iverson, & Brooks, 2009)
4.5 Relationships between DaT and Affect 
The present study found strong inverse associations between DaT availability in 
the left striatum and putamen and motor impulsiveness, such that lower DaT levels were 
associated with greater motor impulsiveness.  Impulsivity is a heterogeneous construct 
and can be broadly divided into decisional (e.g., reduced sensitivity to adverse outcomes 
during learning and risk taking) and motor forms (e.g., impaired inhibition of a prepotent 
response) (Voon et al., 2017).  DaT imaging studies have consistently reported reduced 
striatal DaT availability in patients with PD with ICD symptoms compared to those 
without ICD symptoms (Smith, Xie, & Weintraub, 2016;Voon et al., 2010; Vriend et al., 
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2014).  Small preliminary studies that have found associations between reduced striatal 
DaT availability and increased ICD symptoms in both prevalent (Voon et al., 2014) and 
incident (Vriend et al., 2014) ICD samples.  A large study using data from the PPMI 
database followed patients longitudinally to investigate neurobiological risk factors for 
ICD symptoms.  The sample included patients both on and off DRT.  In patients on DRT, 
a greater decrease in right caudate and mean striatal DaT over the first year was 
significantly associated with an increased risk of incident ICD symptoms.  In addition, 
lower right putamen DaT availability at a given post-baseline visit was associated with 
incident ICD symptoms at that visit in the DRT subgroup (Smith, Xie, & Weintraub, 
2016).   
This relationship between reduced DaT availability and ICD symptoms is not 
entirely clear and several hypotheses have been suggested.  One hypothesis is a more 
pronounced dopaminergic denervation in patients with PD with ICD symptoms.  The 
DaT is the primary mechanism by which dopamine is removed from the synapse to 
terminate its action.  The low DaT concentrations in patients with PD with ICD 
symptoms could result in increased synaptic accumulation and therefore longer duration 
of action for dopamine (Vriend et al., 2014).  Additionally, having a genetic risk factor 
for lower DaT availability or premorbid personality traits predisposing an individual to 
ICD symptoms have also been proposed as possible explanations (Voon et al., 2017; 
Vriend et al., 2014). 
Executive functioning deficits have also been associated with ICD symptoms, 
including impulsive decision making and impaired set-shifting (Voon et al., 2010).   
Dopaminergic medications can have influence cognitive processes by enhancing learning 
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from positive feedback, but impairing learning from negative feedback thereby increasing 
impulsive behaviors.   ICD behaviors in PD tend to be under recognized, in part due to 
the fact that screening is not common and patients may not report symptoms associated 
with ICDs secondary to embarrassment or lack of awareness.  DaT imaging may be a 
useful tool in identifying predictive factors that may guide treatment decisions regarding 
DRT use.  Future studies should also examine the differential role of dopamine agonists 
versus other DRT, as well as the relationship between DaT availability in the four major 
ICDs independently (e.g., compulsive gambling, eating, buying, and sexual behavior). 
4.6 Limitations
While the study provided an important contribution to the literature on the role of 
striatal dopamine on cognitive and emotional functioning in patients with PD, limitations 
must be acknowledged.  First, the patient and control samples were both small and 
varied, as is typical for SPECT imaging studies due to the use of radioactive compounds.  
The study was also limited by low power which may have reduced the possibility of 
finding significant correlations between biological and cognitive variables.  Conversely, 
the significant findings in small samples also raise the possibility of overestimation; 
therefore, the p-values in this small sample should be interpreted with caution.  A related 
methodological concern is Type 1 error (i.e., rejecting the null hypothesis when the null 
is true, a false positive) due to multiple comparisons.  The current study did not involve a 
correction (e.g. Bonferroni) for Type I error due to the exploratory nature of the analyses.  
Further, given the limited sample size, the caution in relying on p-values in small 
samples, and the risk of neglecting Type 2 error, preservation of power was a priority. 
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Additionally, the present study utilized a cross-sectional design, thus significant 
correlations suggest an association between variables but do not imply causation.   
Most PD patients in this sample were on dopaminergic medication at the time of 
their neuropsychological evaluation, which could have influenced the cognitive results by 
potentially ameliorating deficits.  Furthermore it is important to consider our findings in 
the context of the broader scope of neuropathological mechanisms that contribute to 
cognitive dysfunction in PD, beyond those of the striatal dopaminergic system.  Cortical 
and striatal beta-amyloid deposition, alpha-synuclein, genetic variation in the 
microtubule-associated tau (MAPT) H1 haploptype, and the involvement of other 
neurotransmitter systems (e.g., noradrenergic, cholinergic, serotonergic) have 
demonstrated a role in the cognitive deficits seen in PD, particularly in the later stages of 
the disease (Cools, 2006; Halliday, Leverenz, Schneider & Adler, 2016; Kehagia, Barker, 
& Robbins, 2010; Shah et al., 2016).  For the purpose of this study, the neurochemical 
focus was restricted to imaging the nigrostriatal dopamine system, thus our study could 
not account for these other factors known to contribute to cognitive functioning in PD, 
which we acknowledge as a limitation.   Future studies should examine the potential 
interactions of these multiple pathological mechanisms in large samples to fully capture 
the variety of neural underpinnings associated with cognitive functioning in 
PD.  Additional longitudinal studies that follow patients from the early un-medicated 
stages to dementia are also warranted.
4.7 Conclusions
In sum, if cross-validated, the results of the present study suggest that striatal 
dopamine is associated with performance in executive, verbal memory, and visuospatial 
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functions in patients with PD.  However, the literature suggests that the correlates of 
these deficits to DaT availability likely depend on the neuropsychological tasks utilized 
and the severity of the disease in the sample (e.g., early vs. advanced disease).  As the 
disease progresses and with advancing age, the risk of other biological systems and co-
occurring pathology (e.g., senile plaques and neurofibrillary tangles, microvascular 
disease, and cerebral amyloid angiopathy) increases. Clinically, it is important for health 
care professionals to be aware and consider the multiple neurobiological bases of 
cognitive impairment in PD.  In particular, investigations of how deficits early in the 
disease relate to later developments (e.g., dementia) will continue to be increasingly 
important in order to inform disease-modifying therapies. 
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